Trevena Announces Publication of APOLLO-1 Results in The Journal of Pain Research Highlighting Oliceridine’s Potential for Management of Moderate-to-Severe Acute Pain
Trevena, Inc. (TRVN)
Last trevena, inc. earnings: 3/12 07:01 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.trevena.com/investor-relations
Company Research
Source: GlobeNewswire
CHESTERBROOK, Pa., March 11, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ: TRVN), a biopharmaceutical company focused on the development and commercialization of innovative treatment options that target and treat diseases affecting the central nervous system, or CNS, today announced publication of APOLLO-1 (Phase 3) results in The Journal of Pain Research on the effects of oliceridine (TRV130) for management of moderate-to-severe acute pain following bunionectomy. The publication, “APOLLO-1: A randomized placebo- and active-controlled phase III study investigating oliceridine (TRV130), a G protein–biased ligand at the µ-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy,” with lead author, Eugene R Viscusi, M.D.,Professor of Anesthesiology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, is available online at https://www.dovepress.com/journal-of-pain-research-archive41. “In this study, oliceridine was found to
Show less
Read more
Impact Snapshot
Event Time:
TRVN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TRVN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TRVN alerts
High impacting Trevena, Inc. news events
Weekly update
A roundup of the hottest topics
TRVN
News
- Trevena, Inc. (NASDAQ: TRVN) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Trevena, Inc. (NASDAQ: TRVN) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Trevena, Inc. (NASDAQ: TRVN) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Trevena, Inc. (NASDAQ: TRVN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.MarketBeat
- Trevena Reports Fourth Quarter 2023 Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
TRVN
Earnings
- 8/14/23 - Miss
TRVN
Analyst Actions
- 4/2/24 - HC Wainwright
TRVN
Sec Filings
- 4/22/24 - Form 8-K
- 4/19/24 - Form PRE
- 4/9/24 - Form 8-K
- TRVN's page on the SEC website